PTC Therapeutics, Inc. PTCT shares are trading higher by $1.00 (8.6 percent) at $12.30 in Monday's session. Credit Suisse has kept the three-day rally going with an upgrade from Neutral to Outperform and raised its price target from $15.00 to $25.00.
Following a higher open, it retreated and found support just below the top of Friday's range ($11.63), reaching $11.58 before mounting another rally.
The ensuing rebound has taken the issue to a new high for the session at $12.79. That marks the highest level for the issue since it peaked on October 14 at $13.69 and ended that session at $13.27.
Interestingly, the following day it fell to $7.97, when it was received a denial letter from the FDA regarding Translarna for nonsense mutation DMD.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
